Indian Pharma Market sees 12.1 percent growth in August: AIOCD-AWACS Report

Published On 2022-09-07 12:23 GMT   |   Update On 2022-12-07 06:15 GMT
Advertisement

New Delhi: The Indian Pharmaceutical Market (IPM) saw significant growth of 12.1 percent in value and 4.8 percent in volume, in the month of August, 2022, says market research firm All India Organization of Chemists and Druggists (AIOCD-AWACS).

"A robust 12% growth of the IPM seems to be supported by a good volume driven growth for majority of the therapy areas," the AWACS report said. It also claimed that COVID influence had reduced drastically by July 21 last year and most of the therapies had started following the normal seasonal trends. For the month of August 22, price increase led growth seems to be slightly higher than the volume growth.

Advertisement

IPM recorded sales of Rs 16,239 crore for August month, and most of the therapies showed a well balanced double digit value and unit growth.

The fastest growing categories were cardiac which grew at 13 percent, anti-infectives - 13 percent and gastrointestinal - 12 percent. Anti-diabetes and vitamins grew 9 percent respectively. The month of August saw very few launches in the the Sitagliptin Generics segment.

Mankind, Cipla and Glenmark stood out with double digit value and unit growth among top 20 corporate. Meanwhile, Augmentin by GSK, USV's Glycomet GP and Mixtard of Abbott maintained the top ranks at month and MAT level. These remained top 3 selling brands in India.

Further, as per the market research firm, the pharma industry has increased the prices by 10% on drugs under price control, along with monsoon linked infectious diseases due to Wholesale Pricing Index (WPI) inflation-linked price hike permitted by the government.

Key Takeaways

• The initial surge of new introductions and quantity pick up in the Sitagliptin market seems to have plateaued in the month of August. This may be because of the limited patient population available.

• There is a gradual shift seen from Sulphonylureas to DPP4-i over a period of time

• Majority of the therapies in the IPM show a robust value and unit growth indicating strong positive trendlines in the coming months

Medical Dialogues team had earlier reported that IPM had witnessed a significant growth of 14.1% in value and 7.3% in volume in the month of July across all the therapy areas.

Also Read: Indian Pharma Market Sees 14.1 Percent Growth In July Sales: AIOCD-AWACS Report

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News